230 related articles for article (PubMed ID: 34794962)
1. Novel Bile Acid-Dependent Mechanisms of Hepatotoxicity Associated with Tyrosine Kinase Inhibitors.
Saran C; Sundqvist L; Ho H; Niskanen J; Honkakoski P; Brouwer KLR
J Pharmacol Exp Ther; 2022 Feb; 380(2):114-125. PubMed ID: 34794962
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.
Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS
PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
Hartman JC; Brouwer K; Mandagere A; Melvin L; Gorczynski R
Can J Physiol Pharmacol; 2010 Jun; 88(6):682-91. PubMed ID: 20628435
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity.
Leslie EM; Watkins PB; Kim RB; Brouwer KL
J Pharmacol Exp Ther; 2007 Jun; 321(3):1170-8. PubMed ID: 17374746
[TBL] [Abstract][Full Text] [Related]
5. Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs.
Notenboom S; Weigand KM; Proost JH; van Lipzig MMH; van de Steeg E; van den Broek PHH; Greupink R; Russel FGM; Groothuis GMM
Eur J Pharm Sci; 2018 Mar; 115():175-184. PubMed ID: 29309877
[TBL] [Abstract][Full Text] [Related]
6. The C-DILI™ Assay: An Integrated In Vitro Approach to Predict Cholestatic Hepatotoxicity.
Jackson JP; Brouwer KR
Methods Mol Biol; 2019; 1981():75-85. PubMed ID: 31016648
[TBL] [Abstract][Full Text] [Related]
7. A novel differentiated HuH-7 cell model to examine bile acid metabolism, transport and cholestatic hepatotoxicity.
Saran C; Fu D; Ho H; Klein A; Fallon JK; Honkakoski P; Brouwer KLR
Sci Rep; 2022 Aug; 12(1):14333. PubMed ID: 35995956
[TBL] [Abstract][Full Text] [Related]
8. The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity.
Guo YX; Xu XF; Zhang QZ; Li C; Deng Y; Jiang P; He LY; Peng WX
Toxicol Mech Methods; 2015; 25(5):382-7. PubMed ID: 25886055
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs.
Mita S; Suzuki H; Akita H; Hayashi H; Onuki R; Hofmann AF; Sugiyama Y
Drug Metab Dispos; 2006 Sep; 34(9):1575-81. PubMed ID: 16760228
[TBL] [Abstract][Full Text] [Related]
10. Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury.
Li X; Zhong K; Guo Z; Zhong D; Chen X
Drug Metab Dispos; 2015 Nov; 43(11):1751-9. PubMed ID: 26276582
[TBL] [Abstract][Full Text] [Related]
11. Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes.
Ogimura E; Sekine S; Horie T
Biochem Biophys Res Commun; 2011 Dec; 416(3-4):313-7. PubMed ID: 22108051
[TBL] [Abstract][Full Text] [Related]
12. The role of the sodium-taurocholate cotransporting polypeptide (NTCP) and of the bile salt export pump (BSEP) in physiology and pathophysiology of bile formation.
Stieger B
Handb Exp Pharmacol; 2011; (201):205-59. PubMed ID: 21103971
[TBL] [Abstract][Full Text] [Related]
13. The Role of the Sodium-taurocholate Co-transporting Polypeptide (NTCP) and Bile Salt Export Pump (BSEP) in Related Liver Disease.
Lu X; Liu L; Shan W; Kong L; Chen N; Lou Y; Zeng S
Curr Drug Metab; 2019; 20(5):377-389. PubMed ID: 31258056
[TBL] [Abstract][Full Text] [Related]
14. Optimized Hepatocyte-Like Cells with Functional Drug Transporters Directly-Reprogrammed from Mouse Fibroblasts and their Potential in Drug Disposition and Toxicology.
Wu ZT; Yao D; Ji SY; Ni X; Gao YM; Hui LJ; Pan GY
Cell Physiol Biochem; 2016; 38(5):1815-30. PubMed ID: 27160211
[TBL] [Abstract][Full Text] [Related]
15. Function and Expression of Bile Salt Export Pump in Suspension Human Hepatocytes.
Chothe PP; Pemberton R; Hariparsad N
Drug Metab Dispos; 2021 Apr; 49(4):314-321. PubMed ID: 33472814
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA prevents rifampicin-induced liver injury by regulating BSEP/NTCP expression via epigenetic activation of NRF2.
Yang Y; Liu L; Zhang X; Jiang X; Wang L
Liver Int; 2020 Jan; 40(1):141-154. PubMed ID: 31571363
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide mimics transcriptional and post-translational regulation during α-tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes.
González R; Cruz A; Ferrín G; López-Cillero P; Fernández-Rodríguez R; Briceño J; Gómez MA; Rufián S; Mata Mde L; Martínez-Ruiz A; Marin JJ; Muntané J
J Hepatol; 2011 Jul; 55(1):133-44. PubMed ID: 21145864
[TBL] [Abstract][Full Text] [Related]
18. Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.
Sissung TM; Huang PA; Hauke RJ; McCrea EM; Peer CJ; Barbier RH; Strope JD; Ley AM; Zhang M; Hong JA; Venzon D; Jackson JP; Brouwer KR; Grohar P; Glod J; Widemann BC; Heller T; Schrump DS; Figg WD
Mol Pharmacol; 2019 Aug; 96(2):158-167. PubMed ID: 31175181
[TBL] [Abstract][Full Text] [Related]
19. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Feng B; Xu JJ; Bi YA; Mireles R; Davidson R; Duignan DB; Campbell S; Kostrubsky VE; Dunn MC; Smith AR; Wang HF
Toxicol Sci; 2009 Apr; 108(2):492-500. PubMed ID: 19223659
[TBL] [Abstract][Full Text] [Related]
20. Sustained upregulation of sodium taurocholate cotransporting polypeptide and bile salt export pump and downregulation of cholesterol 7α-hydroxylase in the liver of patients with end-stage primary biliary cirrhosis.
Takeyama Y; Kanegae K; Inomata S; Takata K; Tanaka T; Ueda S; Yokoyama K; Morihara D; Nishizawa S; Anan A; Irie M; Iwata K; Shakado S; Sohda T; Sakisaka S
Med Mol Morphol; 2010 Sep; 43(3):134-8. PubMed ID: 20857261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
